Could Faster Biosimilar Development Change the Economics of Biologic Drug Competition?

According to analysis from Kings Research, the global biosimilars market size was USD 37.88 billion in 2025 and is projected to reach USD 133.08 billion by 2033, expanding at a CAGR of 17.01% over the forecast period from 2026 to 2033. This expansion reflects the growing role of biologic therapies across healthcare systems worldwide. Biologics represent a significant share of modern medicine, providing advanced interventions for complex autoimmune conditions, cancers, and genetic disorders. However, their high production costs and strong patent protections present long-term challenges for healthcare budgets.

The U.S. Food and Drug Administration (FDA) reported that biological products account for only 5% of total drug prescriptions yet drive 51% of prescriptions in the country as of 2024. Establishing post-exclusivity pricing pressure through secondary entrants has historically proven far more difficult for complex biopharmaceutical products than for traditional small molecule generics.

A major barrier to increased supply has been the technical and regulatory burden required to demonstrate similarity. To address this, regulatory bodies are refining scientific expectations. In March 2026, the FDA issued updated draft guidance outlining opportunities to streamline redundant clinical pharmacokinetic (PK) testing for proposed biosimilars when scientifically justified. The agency estimated that eliminating unnecessary comparative PK studies could lower PK trial expenses by up to 50%, saving developers approximately USD 20 million per development program.

This shift creates a fundamental question. If bringing a biosimilar through regulatory evaluation becomes faster and requires less capital, how will the economics of competing against established reference biologics evolve?

Answering this requires looking beyond initial scientific approvals:

• Why biological molecules are complex to manufacture and characterize
• How regulatory requirements are shifting toward analytical precision
• What financial metrics influence corporate investment decisions
• How reimbursement mechanisms and post-approval market dynamics shape real-world adoption

Why Biosimilar Development Remains Fundamentally Different from Generic Drug Development

To understand how development economics could shift, one must first recognize why biological medicines diverge from the economic model of traditional generic drugs. Small molecule generic drugs consist of simple, chemically synthesized molecules with well-defined, reproducible structures. 

In contrast, biological products are complex, large molecular weight proteins produced inside living cell lines. Because living organisms express these proteins, minor variations in host cell culture conditions, post-translational modifications (such as glycosylation patterns), or purification steps alter the final molecular structure. A biosimilar lacks the classification of an identical chemical copy of a reference biologic; it must be proven to be highly similar with no clinically meaningful differences in safety, purity, or potency.

The FDA describes advanced analytical characterization as the foundation of biosimilar assessment. Developers evaluate proposed molecules against reference standards across multiple scientific domains:

Where the Biosimilar Development Pathway Could Become More Efficient

Because clinical trials account for a large portion of development spending, regulatory agencies are re-evaluating which trial requirements provide meaningful scientific insights. Accumulated experience across dozens of approved products has shown that high-resolution analytical tools are often more sensitive at detecting structural differences than broad clinical efficacy endpoints.

Key regulatory focus areas for efficiency gains include:

• Streamlined Pharmacokinetic Testing: The FDA's March 2026 draft guidance updated guidelines for clinical PK testing. It removed the standing recommendation that sponsors conduct a direct three-way clinical PK trial against a U.S. licensed reference product if sufficient comparative data from foreign-approved comparator products exists and is scientifically justified. 
• Re-evaluating Phase 3 Efficacy Trials: Regulators are increasingly accepting advanced analytical characterization, receptor binding kinetics, and sensitive immunogenicity assays in place of large Phase 3 comparative trials for straightforward protein structures.
• Leveraging Biomarkers: Utilizing validated pharmacodynamic biomarkers allows sponsors to evaluate biological response faster in early phase subjects rather than waiting for long term clinical endpoints.
• Global Comparator Standards: Accepting foreign-sourced reference products without requiring redundant bridge trials lowers global clinical development costs for international submissions.

These shifts represent an evolution toward risk-based science. By focusing resource allocation on advanced analytical profiling rather than broad clinical trials, regulatory agencies aim to reduce overall entry costs while maintaining strict safety standards.

Faster Approvals Could Increase Competition, but Competition Still Depends on the Pipeline

While lower capital barriers make development more accessible, an easier approval process fails to guarantee a crowded market. Actual supply expansion depends on continuous pipeline activity and long-term capital deployment by biopharmaceutical companies.

Numerous biologics face patent expiries over the next decade that completely lack active biosimilar development programs. This scenario occurs when reference products lose market exclusivity without alternative options ready for commercial launch.

Several structural realities explain why pipeline gaps persist despite regulatory improvements:

1. Long Lead Times: Even under streamlined clinical guidelines, cell line engineering, analytical validation, and scale-up require four to six years of work prior to regulatory filing.
2. First Mover Advantage: The first two or three alternative entrants to reach the market typically capture the majority of newly available market share. Late entrants face diminishing returns, which often deters companies from starting parallel development programs for products that already possess multiple competitors.
3. Manufacturing Infrastructure: Constructing, validating, and operating high-yield biologics facilities demands significant, continuous capital investment.

Industry developments demonstrate how major producers are adjusting their commercial infrastructure to support expanded pipelines:

• Sandoz (August 2026): Announced an investment of approximately USD 300 million to build a new drug substance manufacturing facility in Ljubljana, Slovenia. Utilizing disposable fed-batch technology, the plant adds 8,000 liters of drug substance capacity by 2029 to support its global portfolio strategy.
• Henlius and Sandoz (August 2026):Signed a strategic collaboration agreement covering up to 10 proposed monoclonal antibody and antibody-drug conjugate (ADC) programs. Sandoz agreed to pay upfront, milestone, and option fees totaling up to USD 322 million to leverage the early-stage development platform of Henlius.
• Celltrion (July 2026): Reported second quarter 2026 revenue of KRW 1.3937 trillion and outlined plans to expand its global portfolio to 18 commercial products by 2030, specifically targeting upcoming patent expiries for major oncology and immunology therapies.
• Fresenius Kabi and Polpharma Biologics (July 2026): Announced that the FDA and EMA accepted for regulatory review the dossier for PB016, a proposed biosimilar candidate referencing Entyvio (vedolizumab) for ulcerative colitis and Crohn's disease.

These investments show that while regulatory updates lower clinical testing barriers, sustainable supply requires substantial, long term commitments to global manufacturing networks and early stage development partnerships.

Interchangeability Could Determine How Easily Biosimilars Translate into Real-World Substitution

Regulatory approval confirms that a secondary product is safe and highly similar to its reference drug, but commercial adoption often depends on how easily it can be substituted at the pharmacy level.

The FDA defines an interchangeable biosimilar as a product that meets additional scientific criteria, allowing it to be substituted for the reference product at the retail pharmacy without requiring intervention from the prescribing healthcare provider, subject to individual state pharmacy laws.

Obtaining an interchangeable designation historically required dedicated clinical switching studies, where patients repeatedly alternated between the reference product and the proposed alternative to prove that switching avoided increasing immunogenicity or lowering efficacy. These studies added millions of dollars to development budgets and extended regulatory timelines.

To streamline this process, the FDA has re-evaluated the necessity of routine switching studies, relying instead on cumulative clinical experience and high-resolution analytical comparative data.

• Celltrion (December 2025): Received FDA approval for Omlyclo (omalizumab-igec), the first biosimilar designated as interchangeable with Xolair across prefilled syringe presentations. Celltrion subsequently expanded this portfolio by securing approval for a 300 mg/2 mL formulation to support flexible outpatient administration.

Streamlining interchangeability requirements reduces regulatory friction, allowing alternative products to compete directly at the pharmacy counter and driving higher volume adoption.

Reimbursement May Decide Whether Biosimilar Competition Remains Economically Sustainable

Reimbursement mechanisms play a central role in determining whether post-exclusivity markets remain commercially viable over the long term. Even if a product gains regulatory approval and achieves an interchangeable designation, medical benefit payment models heavily influence provider adoption.

In the United States, physician-administered biologics covered under Medicare Part B and commercial health plans are generally reimbursed using the Average Sales Price (ASP) methodology. Providers purchase the medication up front, administer it to the patient, and receive reimbursement equal to the drug's ASP plus a fixed percentage margin (historically ASP + 6%).

This model can create structural adoption challenges:

1. The ASP Decay Spiral: As manufacturers offer deeper discounts to capture market share, the calculated ASP for that drug declines over subsequent quarters. Over time, lower baseline prices reduce absolute percentage-based reimbursement margins for administering clinics, potentially disincentivizing adoption if operating overhead remains unchanged.
2. Reimbursement Compression: Rapid price drops across competing suppliers can erode profit margins for both manufacturers and clinical providers. If prices decline too quickly, lower-margin suppliers may choose to exit the market.
3. Market Consolidation: If sustained price pressure leaves only one or two suppliers profitable, the market risks supply disruptions or reduced long term price competition.

Without predictable reimbursement frameworks that support both manufacturing costs and clinical distribution, fast development alone fails to sustain a multi-supplier market over time.

Oncology and Other High Value Therapeutic Areas Could Become Important Testing Grounds

The economic impact of streamlined development pathways will vary across therapeutic areas based on clinical complexity, patient volume, and total market size.

According to Kings Research data, the oncology segment represents a major growth driver within the biosimilars sector. The global oncology biosimilars segment is projected to reach USD 58.82 billion by 2033. Monoclonal antibodies represent the largest product class, accounting for 46.76% of total global market value in 2025 (USD 17.71 billion).

Recent industry launches illustrate expanding activity across these core therapeutic categories:

• Biocon Biologics (August 2026): Received marketing approval from Japan's Ministry of Health, Labour and Welfare for its pegfilgrastim biosimilar (referencing Neulasta) to support supportive oncology care, with commercial distribution managed by Sandoz K.K.
• Fresenius Kabi (August 2026): Secured FDA approval for a rituximab biosimilar developed in partnership with Dr. Reddy's Laboratories, expanding access to oncology and autoimmune treatments.

Therapeutic categories with high baseline costs and large patient populations offer clearer opportunities to recover development investments. Consequently, oncology and immunology remain primary testing grounds for evaluating new development guidelines.

Europe, the U.S., and Asia Pacific Are Approaching Biosimilar Competition Differently

Geographic regions use different regulatory frameworks, purchasing models, and commercial structures to manage biopharmaceutical competition.

Data from Kings Research indicates that Europe held the largest share of the global biosimilars sector in 2025, accounting for 52.38% of global revenue (USD 19.84 billion). Meanwhile, the Asia Pacific region is projected to experience the fastest growth, expanding at a CAGR of 17.38% from 2026 to 2033.

Market structures differ across key geographic regions:

While European healthcare systems rely on centralized tendering to convert lower development costs into immediate system savings, the U.S. market depends on a combination of regulatory streamlining and formulary access reforms. Simultaneously, expanding manufacturing capabilities across Asia Pacific are lowering global production costs.

Conclusion: What Faster Biosimilar Development Could Mean for the Biologic Industry's Competitive Model

Streamlining clinical evaluation and lowering up-front testing costs is changing how biopharmaceutical companies evaluate post-exclusivity opportunities. Combining regulatory changes with shifting corporate strategies points toward three key market developments:

1. Broader Product Pipelines: Lower entry costs allow companies to target specialized or mid-tier biologics rather than focusing exclusively on blockbuster therapies. This could bring post-exclusivity competition to previously underserved therapeutic areas.
2. Faster Market Entry: Eliminating redundant clinical studies reduces development timelines by several years. Secondary suppliers can better align their regulatory submissions with patent expiration dates, shortening the period of unchallenged market dominance for reference products.
3. Higher Reliance on Manufacturing Efficiency: As scientific and regulatory barriers decrease, long term commercial advantage will depend heavily on manufacturing scale, yield optimization, and secure supply chains. Companies with advanced continuous manufacturing or flexible bioprocessing platforms will be better positioned to maintain profitability amid falling prices.

Lowering development costs addresses a key structural barrier, but long term market competitiveness will depend on post approval adoption and distribution mechanisms. The next phase of biopharmaceutical competition will be shaped largely by how efficiently global healthcare systems convert new approvals into accessible, cost-effective treatment options.

Ready to explore how shifting healthcare dynamics impact your commercial strategy? As regulatory pathways become more efficient and market competition intensifies, staying ahead of the biologic pipeline is essential for sustainable growth. Reach out to our biopharmaceutical advisory team today to discuss how your organization can navigate evolving development economics, optimize manufacturing investments, and secure long-term market access.

FAQs

Why is developing a biosimilar more expensive than developing a generic drug?

Generic drugs are simple, chemically synthesized molecules that require straightforward bioequivalence testing. Biosimilars are large, complex proteins grown in living cells. Developers must conduct extensive analytical characterization, immunogenicity testing, and pharmacokinetic evaluations to prove structural and functional similarity, significantly increasing development budgets.

How is the FDA streamlining the approval process?

The FDA is modernizing its approach by focusing on high-resolution analytical data rather than broad clinical trials. Recent draft guidance allows developers to eliminate redundant clinical pharmacokinetic (PK) testing when scientifically justified, which can reduce certain trial costs by up to 50%.

Will cheaper development costs immediately lead to lower prices for patients?

Lowering development costs reduces the barrier to entry, but post-approval pricing depends heavily on the volume of competitors that enter the market. Substantial price erosion typically occurs only after multiple independent suppliers launch competing products.

What is an interchangeable biosimilar?

An interchangeable biosimilar meets additional regulatory criteria allowing pharmacists to substitute it for the reference product without needing prior authorization from the prescribing doctor, subject to individual state pharmacy laws.

Which therapeutic areas are seeing the highest biosimilar investment?

Oncology, immunology, and metabolic disorders receive the most focus due to their large patient populations, chronic treatment protocols, and high baseline costs, which present viable commercial opportunities for developers.